Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms

Translational Neurodegeneration

Review

Pei Huang¹  Yu-Yan Tan¹  Sheng-Di Chen²  Lin-Yuan Zhang³ 

[1] Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China;Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China;Lab for Translational Research of Neurodegenerative Diseases, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), Shanghai Tech University, 201210, Shanghai, China;Department of Neurology, Shanghai General Hospital, 200080, Shanghai, China;

关键词: COVID-19;    SARS-CoV-2;    Parkinson’s disease;    Alzheimer’s disease;    Mechanism;   

DOI  :  10.1186/s40035-023-00337-1

 received in 2022-09-29, accepted in 2023-01-12,  发布年份 2023

来源: Springer

【 摘 要 】

The impact of coronavirus disease 2019 (COVID-19) pandemic on patients with neurodegenerative diseases and the specific neurological manifestations of COVID-19 have aroused great interest. However, there are still many issues of concern to be clarified. Therefore, we review the current literature on the complex relationship between COVID-19 and neurodegenerative diseases with an emphasis on Parkinson’s disease (PD) and Alzheimer’s disease (AD). We summarize the impact of COVID-19 infection on symptom severity, disease progression, and mortality rate of PD and AD, and discuss whether COVID-19 infection could trigger PD and AD. In addition, the susceptibility to and the prognosis of COVID-19 in PD patients and AD patients are also included. In order to achieve better management of PD and AD patients, modifications of care strategies, specific drug therapies, and vaccines during the pandemic are also listed. At last, mechanisms underlying the link of COVID-19 with PD and AD are reviewed.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

42004_2022_800_Article_IEq83.gif